Reports Q4 revenue $168.4M, consensus $169.06M. “Harmony delivered another year of outstanding performance in 2023, with continued strong growth for WAKIX, demonstrating its durability going into year five on the market,” stated Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony. “In addition to our strong commercial execution, we advanced all our clinical development programs for pitolisant, moved the Next-Generation formulations of pitolisant into the clinic, expanded our pipeline and diversified our portfolio with the acquisition of Zynerba and the ongoing Phase 3 trial in Fragile X syndrome. Harmony continues to be a growth story and we look forward to continued strong execution in 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences Releases Investor Presentation Update
- Harmony Biosciences: FDA grants priority review for sNDA for WAKIX
- Harmony Biosciences’ pitolisant designated Orphan Drug in Prader-Willi syndrome
- Harmony Biosciences price target raised to $42 from $33 at Mizuho
- Harmony Biosciences’ treatment of PWS receives FDA orphan designation
